WDWilliam R. Davis

William R. Davis

*This is an algorithmically generated author record based on publicly available information.

William R. Davis has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    MDL ‐800–Induced Sirtuin 6 Activation Decreases Age‐Associated Osteoarthritis in Mice

    by Matheus Moreira Perez, Pranay Ramteke, Bahiyah Watson, Owen Haslam, Eirene Choi, Susan Chubinskaya, Mandy J. Peffers, William R. Davis, Jacqueline Shine, Brian O. Diekman, et al.

    Objective: Sirtuin 6 (SIRT6) is a nuclear‐localized histone deacetylase that regulates multiple pathways associated with aging. This study aimed to determine whether systemic administration of MDL‐800, a small molecule activator of SIRT6, decreases the severity of age‐associated osteoarthritis (OA) in mice. Methods: Male, 18‐month‐old mice received weekly intraperitoneal injections of MDL‐800 or vehicle control for 6 months, and OA severity was assessed at 24 months using histology, micro–computed tomography, and histomorphometry. The role of MDL‐800–induced SIRT6 activation in human chondrocyte function was analyzed using RNA sequencing and immunoblotting. The effect of MDL‐800 to reduce DNA damage was assessed in human and mouse synovial fibroblasts by the comet assay. Results: Mice receiving long‐term administration of MDL‐800 were protected from OA pathology when compared to controls, as characterized by less cartilage damage, osteophyte formation, synovial hyperplasia, subchondral bone sclerosis, and meniscal ossification. RNA sequencing of chondrocytes revealed that MDL‐800 negatively enriched pathways associated with bone formation, angiogenesis, and catabolic MAPK signaling, while positively enriching pathways associated with epigenetic regulation, telomere maintenance, mitochondrial function, redox balance, and DNA repair. MDL‐800 significantly decreased oxidative stress‐induced phosphorylation of p38 in chondrocytes and basal DNA damage in human and mouse synovial fibroblasts. Conclusion: Activation of SIRT6 by MDL‐800 significantly protected old mice from age‐associated OA severity in vivo. MDL‐800 decreased pathways associated with pathologic bone formation and regulated multiple hallmarks of aging. Targeted therapies that activate SIRT6 may represent a novel strategy to repress multiple aging pathways to slow, stop, or reverse age‐associated OA.

  • Open Access

    Extended oral antibiotic prophylaxis does not reduce periprosthetic joint infection after primary outpatient total shoulder arthroplasty: A matched cohort analysis

    by Bradley J Lauck, Nicholas C Bank, William R Davis, Charles B Colson, Stephen Himmelberg, Brian R Waterman, Alan W Reynolds

    Background: Over the last decade, total shoulder arthroplasty (TSA) has increasingly transitioned to the outpatient setting, where postoperative care pathways inherently limit the ability to deliver a full 24 hour course of intravenous antibiotic prophylaxis. Despite guideline recommendations, extended oral antibiotic prophylaxis is variably used after outpatient TSA, with limited evidence supporting this practice. Methods: A retrospective cohort study using the TriNetX database identified patients undergoing primary outpatient TSA between 2015 and 2025. Patients were stratified by receipt of extended oral antibiotic prophylaxis. Propensity score matching yielded two cohorts of 2647 patients each. Outcomes included periprosthetic joint infection (PJI), surgical site infection (SSI), all-cause revision, wound disruption, and emergency department utilization at 90 days and 1 year. Risk ratios (RRs) with 95% confidence intervals (CIs) were calculated. Results: At 90 days, there were no significant differences in PJI (0.9% vs 0.5%; RR 1.20, 95% CI 0.96–3.84) or SSI (0.8% vs 0.5%; RR 1.67, 95% CI 0.82–3.40). At 1 year, PJI (1.6% vs 1.2%; RR 1.34, 95% CI 0.85–2.12) and SSI (1.1% vs 0.8%; RR 1.14, 95% CI 0.79–2.42) rates remained comparable between groups. Discussion: Extended oral antibiotic prophylaxis did not reduce infection-related outcomes following primary outpatient TSA. Level of evidence: III, Retrospective cohort study.

  • Open Access

    How do GLP-1 receptor agonists influence the progression of shoulder pathology? A matched cohort analysis

    by William R. Davis, Nicholas C. Bank, Bradley J. Lauck, Robert A. Creighton, R. Justin Mistovich